120 related articles for article (PubMed ID: 37083815)
1. Pan-cancer analysis of aldolase B gene as a novel prognostic biomarker for human cancers.
Zhao N; Xu H
Medicine (Baltimore); 2023 Apr; 102(16):e33577. PubMed ID: 37083815
[TBL] [Abstract][Full Text] [Related]
2. Aldolase B inhibits metastasis through Ten-Eleven Translocation 1 and serves as a prognostic biomarker in hepatocellular carcinoma.
Tao QF; Yuan SX; Yang F; Yang S; Yang Y; Yuan JH; Wang ZG; Xu QG; Lin KY; Cai J; Yu J; Huang WL; Teng XL; Zhou CC; Wang F; Sun SH; Zhou WP
Mol Cancer; 2015 Sep; 14():170. PubMed ID: 26376879
[TBL] [Abstract][Full Text] [Related]
3. ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma.
Shao Y; Wu B; Yang Z; Liu Z; Ma Y; Huang H; Liu Y; Wang Z; Hu W; Wang Y; Niu Y
Transl Androl Urol; 2023 Apr; 12(4):549-571. PubMed ID: 37181232
[TBL] [Abstract][Full Text] [Related]
4. Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma.
Li Q; Li Y; Xu J; Wang S; Xu Y; Li X; Cai S
Cell Physiol Biochem; 2017; 42(1):397-406. PubMed ID: 28558381
[TBL] [Abstract][Full Text] [Related]
5. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
6. Aldolase B impairs DNA mismatch repair and induces apoptosis in colon adenocarcinoma.
Lian J; Xia L; Chen Y; Zheng J; Ma K; Luo L; Ye F
Pathol Res Pract; 2019 Nov; 215(11):152597. PubMed ID: 31564566
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
Peng SY; Lai PL; Pan HW; Hsiao LP; Hsu HC
Oncol Rep; 2008 Apr; 19(4):1045-53. PubMed ID: 18357395
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
9. High Expression of Aldolase B Confers a Poor Prognosis for Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy.
Tian YF; Hsieh PL; Lin CY; Sun DP; Sheu MJ; Yang CC; Lin LC; He HL; Solórzano J; Li CF; Chang IW
J Cancer; 2017; 8(7):1197-1204. PubMed ID: 28607594
[No Abstract] [Full Text] [Related]
10. Fructose-1,6-Bisphosphate Aldolase B Depletion Promotes Hepatocellular Carcinogenesis Through Activating Insulin Receptor Signaling and Lipogenesis.
Liu G; Wang N; Zhang C; Li M; He X; Yin C; Tu Q; Shen X; Zhang L; Lv J; Wang Y; Jiang H; Chen S; Li N; Tao Y; Yin H
Hepatology; 2021 Dec; 74(6):3037-3055. PubMed ID: 34292642
[TBL] [Abstract][Full Text] [Related]
11. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract][Full Text] [Related]
12. Aldolase B suppresses hepatocellular carcinogenesis by inhibiting G6PD and pentose phosphate pathways.
Li M; He X; Guo W; Yu H; Zhang S; Wang N; Liu G; Sa R; Shen X; Jiang Y; Tang Y; Zhuo Y; Yin C; Tu Q; Li N; Nie X; Li Y; Hu Z; Zhu H; Ding J; Li Z; Liu T; Zhang F; Zhou H; Li S; Yue J; Yan Z; Cheng S; Tao Y; Yin H
Nat Cancer; 2020 Jul; 1(7):735-747. PubMed ID: 35122041
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics analysis of the role of aldolase A in tumor prognosis and immunity.
Tian W; Zhou J; Chen M; Qiu L; Li Y; Zhang W; Guo R; Lei N; Chang L
Sci Rep; 2022 Jul; 12(1):11632. PubMed ID: 35804089
[TBL] [Abstract][Full Text] [Related]
14. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
15. Aldolase B attenuates clear cell renal cell carcinoma progression by inhibiting CtBP2.
Tan M; Pan Q; Wu Q; Li J; Wang J
Front Med; 2023 Jun; 17(3):503-517. PubMed ID: 36790589
[TBL] [Abstract][Full Text] [Related]
16. Prognostic values of ALDOB expression and
Jia W; Wu Q; Yu X; Shen M; Zhang R; Li J; Zhao L; Huang G; Liu J
Front Oncol; 2022; 12():1044902. PubMed ID: 36644641
[TBL] [Abstract][Full Text] [Related]
17. Elucidating cuproptosis-related gene SLC31A1 diagnostic and prognostic values in cancer.
Mi J; Luo J; Zeng H; Zhang H; Jamil M; Abdel-Maksoud MA; Zakri AM; Alfuraydi AA; Zhang N; Xiao M
Am J Transl Res; 2023; 15(10):6026-6041. PubMed ID: 37969191
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
19. Dual effects of fructose on ChREBP and FoxO1/3α are responsible for AldoB up-regulation and vascular remodelling.
Cao W; Chang T; Li XQ; Wang R; Wu L
Clin Sci (Lond); 2017 Feb; 131(4):309-325. PubMed ID: 28007970
[TBL] [Abstract][Full Text] [Related]
20. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Sun K; Chen RX; Li JZ; Luo ZX
Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
